Molnupiravir is given to treat mild-to-moderate COVID-19 in adults ages 18 and older who are at high risk for progression to severe COVID-19, including hospitalization or death, and when alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate and who meet the current Priority Eligibility Criteria.
Frequently Asked Questions About Molnupiravir
On December 23, 2021, the FDA issued an EUA for molnupiravir (MERCK) for the treatment of mild to moderate COVID 19 in adults who are at high risk for progression to severed COVID-19, including hospitalization of death, meet Michigan prioritization criteria, and for whom alternative COVID - 19 treatment options are not accessible or clinically appropriate.
A qualified healthcare provider will determine whether molnupiravir is an appropriate treatment and when an individual will receive the medication.
How does molnupiravir work?
Molnupiravir works by teaching the virus that causes COVID-19 to mutate (genetically change), which causes the virus to become unable to reproduce, which keeps you from getting sicker.
Who can take molnupiravir?
A qualified healthcare provider may prescribe molnupiravir for patients with the following:
Molnupiravir should only be used for those who don't have timely access to alternative COVID-19 medications (like monoclonal antibody therapy) and when the patient can start the medication within 5 days of symptom onset.
Can I take molnupiravir if I'm pregnant or breastfeeding?
Molnupiravir should not be used for anyone who is pregnant/and or breastfeeding.
How is molnupiravir given?
Further information for patients and caregivers can be found at: Fact Sheet for Patients and Caregivers Emergency Use Authorization (EUA) Of Molnupiravir
How much will molnupiravir cost me?
Currently, molnupiravir is provided by the federal government at no charge to you. Pharmacies dispensing molnupiravir may bill insurance providers for the cost of dispensing the medication. Patients should not experience out-of-pocket costs.